within Pharmacolibrary.Drugs.ATC.L;

model L01BC01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.017333333333333333,
    adminDuration  = 600,
    adminMass      = 0.1,
    adminCount     = 1,
    Vd             = 0.0007700000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Cytarabine (also known as Ara-C) is a cytosine nucleoside analog used primarily as an antimetabolite chemotherapy agent for the treatment of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and non-Hodgkin's lymphoma. It inhibits DNA synthesis in rapidly dividing cells. Cytarabine is an approved and widely used chemotherapy drug.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters from adults with acute myeloid leukemia treated via intravenous infusion; values reflect population pharmacokinetics.</p><h4>References</h4><ol><li><p>Crook, KI, et al., &amp; Papich, MG (2013). The pharmacokinetics of cytarabine in dogs when administered via subcutaneous and continuous intravenous infusion routes. <i>Journal of veterinary pharmacology and therapeutics</i> 36(4) 408–411. DOI:<a href=&quot;https://doi.org/10.1111/jvp.12008&quot;>10.1111/jvp.12008</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22943060/&quot;>https://pubmed.ncbi.nlm.nih.gov/22943060</a></p></li><li><p>Cornely, OA, et al., &amp; Hodges, MR (2023). Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia. <i>The Journal of antimicrobial chemotherapy</i> 78(11) 2645–2652. DOI:<a href=&quot;https://doi.org/10.1093/jac/dkad269&quot;>10.1093/jac/dkad269</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37681450/&quot;>https://pubmed.ncbi.nlm.nih.gov/37681450</a></p></li><li><p>Eckstein, OS, et al., &amp; McClain, KL (2023). Treatment of Langerhans cell histiocytosis with subcutaneous cytarabine. <i>Pediatric hematology and oncology</i> 40(5) 497–505. DOI:<a href=&quot;https://doi.org/10.1080/08880018.2022.2137609&quot;>10.1080/08880018.2022.2137609</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36625721/&quot;>https://pubmed.ncbi.nlm.nih.gov/36625721</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01BC01;
